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Abstract 
Purpose:  To analyse whether the screening performance parameters of the Maltese National 
Breast Screening Programme first screening round met requirements set by European 
standards. The association between screening age and results of screening performance 
parameters was also investigated.  
Method: Quantitative methodology was used to review examinations of women who were 
recalled for a technical recall or further assessment rates. All accessible members of the 
population recalled during the first round were retrospectively reviewed resulting in a sample 
of 2300 recalled examinations.  
Results: Malta’s first screening round met the European Guidelines recommendations for 
technical repeat rate (0.26%), early recall rate (0.45%), breast cancer detection rate (13.77 per 
1000 women) and Positive Predictive Value of screening test (7.58%). However, local recall 
rate (18.53%) and further assessment rate (18.27%) were higher than recommended.  
The Chi square test showed a statistically significant difference (p<0.05) in recall rates 
between the compared age groups, as younger women (51-55 years) were more likely to have 
a negative diagnosis after the initial mammogram whereas older women (56-60 years) were 
more likely to be recalled. There was no age discrepancy (p>0.05) in local breast cancer 
detection rate and positive predictive value of screening test. 
Conclusion: Although the Maltese first screening round performed well, this study found 
deficiencies in recall and further assessment rates, which according to literature may result in 
psychological morbidity and inefficient use of screening resources. This study also concluded 
that when a cohort is analysed, age is not as significant as the screening round itself 
(first/subsequent). 
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Introduction 
Breast cancer is the most common cancer among Maltese women and accounts for a third of 
all female cancer deaths. Every one in twelve Maltese women will get breast cancer in her 
lifetime; a significantly higher proportion than the European average.
1
 In October 2009, 
Malta’s Department for Health agreed to implement a National Breast Screening Programme 
(MNBSP).
2
 
 
 The aim of screening was to reduce morbidity and mortality from the disease 
without adversely affecting the health of participants.
3,4
  
 
Key to achieving this aim were high 
levels of quality within the entire screening process.
4
  The MNBSP strives to protect the 
dignity and privacy of women, while offering an effective service at the highest levels of 
quality to diagnose and treat breast cancers at the earliest possible stage, and also meeting the 
European clinical standards.
4
 
 
The first MNBSP round commenced in October 2009 and ended in February 2013. The local 
screening programme provided free screening, every three years for all women aged 50 to 60, 
resident in the Maltese Islands. This age range was selected for the first screening round since 
this age group was deemed to be the ‘most at risk’ of developing breast cancer.1 Malta’s 
Department for Health additionally states that as soon as more human resources became 
available, the programme will be extended even to older women.
1
  
 
Double reading of mammograms was performed locally, as recommended for programmes in 
their first round of screening.
4   When comparing dual to single reading, studies have shown 
that sensitivity increased by 5–10% without a significant effect on recall rates.5 Consensus 
arbitration of discordant double read cases also improved reading performance since it 
decreased recall rates and increased Positive Predictive Value (PPV).
4,6,7
 Since consensus 
arbitration was not practised locally, as per radiologists’ choice, women who were recalled by 
one radiologist experienced additional examinations during further assessment clinics. This 
could have resulted in higher recall rates and lower PPV.  
  
A high quality screening service can be achieved through the use of targets, performance 
parameters and audits.
4
 Although audits of performance parameters were undertaken in 
European screening units, this research was the first of its kind in Malta. The findings offer 
valuable contribution for future advancement of the local screening unit as they helped to 
identify areas of strength, as well as areas needing improvement.  
 
This study aimed to retrospectively audit results of the first screening round of the MNBSP 
and to assess whether the service fulfilled the European standard requirements. Thus the 
study objectives were to measure screening performance parameters (Recall Rate, Technical 
Recall (TR) Rate, Further Assessment Rate, Early Recall (ER) Rate, Breast Cancer Detection 
Rate, PPV of Screening Test) of the local first screening round; calculate the different types 
of clinical examinations performed during further assessment clinics; compare the rates of the 
screening performance parameters to the levels set by European and United Kingdom (UK) 
guidelines and investigate any association between screening age and results of screening 
performance parameters. 
Literature Review 
Several online databases such as Medline, Cumulative Index Nursing and Allied Health 
Literature, and ScienceDirect were utilised to access e-journals. Although most of the 
identified literature was undertaken after the inception of screening programmes, around 10–
20 years ago, it was seminal to the study and was therefore included in this review. Only 
peer-reviewed, European studies written in the English language were included due to the 
similarity of breast screening programmes.  
 
Quality Assurance (QA) 
Ensuring the quality of a screening service is vital. This could be achieved by early 
monitoring of screening performance parameters of the unit, potentially optimising the use of 
resources and ultimately producing an observable reduction in mortality.
4
  Strict adherence to 
quality assurance and quality control guidelines must be practised in all mammography 
facilities to ensure accurate diagnosis, thus minimising false positive mammograms.
8,9
 False-
positive rate refers to recalls for further assessment which turn out to be normal or benign.
10
 
This is one of the reasons for the ongoing screening debate, since it gives rise to negative 
effects, namely: financial costs to the health service and psychological strain on the 
women.
10,11 
Since the majority of screening mammograms are normal, radiologists’ record of 
reporting should demonstrate high specificity avoiding false-positive mammograms.
12 
 
In addition to false positive rates, several other performance parameters were identified by 
‘The European Guidelines for QA in Breast Cancer Screening and Diagnosis’. 
Recommended acceptable levels for each parameter were also set.
4
  
 
Table 1 defines the 
screening performance parameters audited in this study and indicates the acceptable EU and 
UK levels for programmes in their first screening round.
 1,4,13,14 ,15 
Several research studies investigated these screening performance parameters. 
Recall Rate 
No increase in cancer detection rates and in screening sensitivity beyond a recall rate of 4.8% 
were recorded.
16
 High recall rates were found to signify that resources are used inefficiently 
in women undergoing unnecessary follow-up procedures.
17,18
   Conversely, rates lower than 
1% were associated with reduced cancer detection and increased interval cancers.
4
 Previous 
research states that recall rates were influenced by several factors including training and 
experience of radiologists, image quality, the volume of mammograms interpreted and the 
age of screened women.
19,20,21  
 
Early Recall Rate 
 ER was found to be associated with a low predictive value for malignancy and thus every 
effort should be made to obtain a definitive diagnosis at initial assessment.
 4,22,23,24
 
Additionally, a study analysing 110 women who were recalled early, revealed that 3.6% had 
invasive cancer, 0.9% had DCIS, while 84% had benign findings.
25 
 
PPV of Screening Tests 
The European guidelines did not define an acceptable PPV of Screening Test, whilst the UK 
National Health Service Breast Screening Programme (NHSBSP) defined the minimum 
standard PPV as 2.7% or more at first screenings.
26
  
 
Due to the similarity between the UK 
NHSBSP and the MNBSP, this value was taken and accepted as the recommended level.
27
 
Although recall rates of first screening rounds are generally high, the PPVs are usually low. 
In subsequent screenings the previous investigations could be referred to without the need for 
recall. Therefore only new findings would be fully investigated, thus lowering recall rates and 
further increasing PPV.
28,
 
20  
 
Performance in European Breast Screening Programmes 
Performance indicators for mammography screening in 17 European countries showed some 
discrepancies, with recall rates ranging from 1.3% to 18.4%.
29
 First screening rounds resulted 
in detection rates varying from 10.7 per 1000 women screened in Copenhagen to 3.6 per 
1000 in Finland.
 29, 30
 This difference between countries should be interpreted with caution 
due to variations in screening and interpretation methods used within the various 
programmes. For instance the UK NHSBSP and the Netherlands followed very different 
recall policies; the latter deliberately aiming at a very low recall rate.  Other differences 
included the use of one versus two-view mammography, screening interval, double-reading 
and methods for arriving at a resolution when double-reading led to different conclusions.
 29, 
30 
 
Effect of Age 
Age is another independent factor predicting the accuracy of screening mammography.
31, 32 
 
As screening age increased, recall rates decreased. Sensitivity, specificity and PPV increased 
with age thus increasing the accuracy of screening. 
31, 32 
 
 
A study that analysed 215,665 mammograms revealed that the PPV was inversely related to 
the recall rates for age.
 31 
Recall rates decreased from 7.3% for the youngest women to 4.9% 
for the oldest women, whilst the PPV rose from 1.9% to 12.7%. This outcome was supported 
by an extensive study of 1.5 million examinations reporting an increase in PPV by age. 
33
 
This was reasonable given the relatively higher breast density and lower incidence of disease 
in younger women. 
34, 20
 
 
Alternatively, studies analysing cohorts of women undergoing successive screening rounds 
indicated no clear association between age and risks of false-positive mammograms, 
concluding that such risks are much higher in first screening rounds.
35, 36
 Nevertheless, there 
were no considerable reductions from second rounds onwards, regardless of women’s 
increasing age. Therefore, the association between age and false-positive recall rates seen in 
several cross-sectional studies could be overestimated because of the proportion of young 
women without a previous mammogram in first screening rounds. This implies that age is not 
as significant as the first screening round itself. 
35 
 
 
Psychological Impact of Recall 
One of the reasons for maintaining screening performance parameters within the acceptable 
EU/UK levels is that women undergoing further assessment suffer significantly greater 
adverse psychological consequences when compared to those with an immediate normal 
result.
37
 One study found that 30% of recalled women felt very anxious on receipt of their 
recall letter, whilst another study reported that 40% of women reported feeling very 
frightened when they received their recall letter.
 38, 39
   16% of respondents felt certain that 
they had breast cancer.
 38,39
   Such a psychological impact was reported by recalled women 
before 
40
, during 
41
, and immediately after recall.
42
 Women who had clear results after an 
invasive investigation and those who were placed on ER experienced the highest levels of 
anxiety.
43,44 
The adverse psychological impacts of false-positive recalls could discourage women from re-
attending for subsequent screening.
45
 Absenting from screening consequently negates any 
benefits of the service and increases the mortality rate. 
46 
To ensure accurate and low false-
positive recall rates it is important to regularly measure screening performance parameters 
and provide feedback to screening personnel.
47 
Methods 
Following ethical approval, a quantitative, non-experimental, descriptive, comparative, 
retrospective design was used to audit the examinations of women who were recalled for 
either a TR or further assessment. The study was conducted at the Maltese screening unit on 
the basis of data obtained from computerised databases.  After every recall session, 
radiographers are responsible for recording all pertinent data on a database at the unit. This 
included recommended and performed TR and further assessments and outcomes of the recall 
clinics. All the women recalled during the first screening round (October 2009 to February 
2013) were included in this study (n=2300).  Retrospective data collection was performed 
between the 4
th
 and 30
th
 August 2014. 
The information was audited by means of three data record sheets derived from the 4th 
edition of the European guidelines for QA in breast cancer screening and diagnosis.
4
 To 
provide a more sensitive measure of performance and to be able to investigate the effect of 
age on each parameter, data was further classified in age groups (51 to 55 and 56 to 60 years).
 
4 
 
Data Record Sheet 1 (Table 2) was used to audit the possible outcomes of the initial 
screening mammogram, namely Negative Examinations, Radiologist Recommended TR, 
Actually Performed TR, Radiologist Recommended Further Assessment and Actually 
Performed Further Assessment.  
 
Data Record Sheet 2 (Table 3) was utilised to audit investigations performed during further 
assessment clinics, namely the Number of Clinical Breast Examinations, the Number of 
Additional Imaging, which was subdivided into Number of Further Views and Ultrasounds, 
and Number of Interventional Procedures, which was subdivided into Number of Radiologist 
Recommended Cytology and Actually Performed Cytology and Number of Radiologist 
Recommended WCNB and Actually Performed WCNB. 
 
Data Record Sheet 3 (Table 4) was used to audit the outcome of the overall screening 
process, namely the Total Negative Examinations, ER following Further Assessment, Number 
of DCIS cases, Number of Invasive Cancers detected and Unknown Outcome.  Data Record 
Sheet 3 was also used to audit the timing of breast cancer detection, namely At Initial Screen 
and During ER.  
 
The researcher undertook the following process for data collection: 
Recalled women were classified either as recommended TR or as recommended recall for 
further assessment. Such classification was opted for, for the sake of consistency with 
terminology used at the unit. The number of recommended and performed TRs and further 
assessments were audited. Data from each recalled woman was then reviewed. This served to 
audit: the number of women who had a clinical breast examination, the number of women 
who had additional imaging (further views or ultrasound); the number of women who 
underwent an interventional procedure (FNA or WCNB). 
 
The number of women recalled for further assessment and classified as requiring an ER was 
also audited. Cases that had undergone interventional procedures were reviewed to determine 
whether any malignancy had been diagnosed. The type of cancer diagnosed was also 
documented and diagnosed cancers were audited according to the time of their detection (at 
the initial screen or during ER).  
 
Descriptive statistics were used to present the audit results and to calculate screening 
performance parameters for the MNBSP.
48
 The chi-square test was used to establish whether 
there was an association between categorical variables.
49
 One of the categorical variables was 
the age group (51-55; 56-60) whilst others described the screening performance parameters. 
The difference between two proportions test was used to determine whether local screening 
performance parameters that failed to meet acceptable levels set by European guidelines, 
differed significantly from the guidelines.  
 
Results 
The audit results and rates of screening performance parameter rates of the Maltese first 
screening round are summarised in Table 2-5. The MNBSP met the recommendations given 
by European Guidelines for TR, ER and breast cancer detection rates which were found to be 
0.26%, 0.45%, 13.77 per 1000 women respectively.
4 
  The PPV of the Screening Test for the 
Maltese first screening round was 7.58%, thus within the recommendations by the UK 
NHSBSP.
26
 However, local recall and further assessment rates (18.53% and 18.27% 
respectively) were higher than those recommended by European guidelines (Table 6).  
The majority of recalled women (n=2251, 83.3%) underwent additional imaging (further 
views or ultrasound); whilst only 23 (0.9%) were examined clinically, 427 (15.8%) women 
underwent interventional procedures (FNA and WCNB).  A total of 27 (0.2%) women were 
diagnosed with DCIS, whilst 144 (1.2%) women were diagnosed with invasive breast cancer. 
The majority of cancers (n=169, 98.8%) were detected at the initial screen whilst 2 (1.2%) 
cancers were detected in women for whom on ER assessment was recommended at further 
assessment.   
 
The Chi square test showed a statistically significant difference (p<0.05) in recall rates 
between the compared age groups, as younger women (51 to 55 years) were more likely to 
have a negative diagnosis after the initial mammogram, whereas older women (56 to 60 
years) were more likely to be recalled. There was no age discrepancy (p>0.05) in the local 
breast cancer detection rate and PPV of the screening test.  
 
Discussion 
Higher recall rates were expected for first screening rounds when compared to subsequent 
ones. The local Recall Rate for the first screening round was higher than the acceptable rate 
for first screening rounds 
28, 35
 and also higher than European recall rates.
29  
The different 
screening and/or interpretation methods utilized locally may account for the differences in 
recall rates leading to issues of comparability of findings to other studies and European recall 
rates. 
 
Differences in data collection may have also affected comparability of recall rates. Although 
this research did not investigate the effect of breast density on mammography performance, 
studies have shown that this factor could affect the performance parameters.
32
 Screening 
programmes recording breast density demonstrated a great variation in breast density 
classification affecting comparisons of screening results. 
 
The presence of symptoms at screening was another important modifier of performance 
estimates, as symptomatic women may have higher recall and PPV rates.
31
 A few 
programmes, including the local one, recorded symptoms present at the time of screening. 
This factor was not included in the pre-established data record sheets and was therefore not 
investigated in this research. 
 
Whilst low recall rates may decrease detection rates and increase incidence of subsequent 
interval cancers, high recall rates alternatively cause psychological morbidity and indicate 
inefficient use of screening resources.
4,35 
Additionally, differences in recall rates may have been affected by factors which were 
beyond the researcher’s control, such as the prevalence of cancer in the population, 
radiologists’ training, image quality, and in some instances, malpractice concerns. The 
training of radiologists is an important factor affecting the recall rate.
21 
The researcher had no 
evidence whether this factor affected the recall rate locally. However, the fact that this was 
the first experience for local radiologists to work within a screening program might have had 
an impact on the recall rate as acknowledged in literature.
21 
Local radiologists might have 
also recalled women with suspicious findings, even in the absence of a possibility of cancer, 
to avoid possible malpractice litigation. Additionally, reading an average of 3600 
mammograms yearly, local radiologists are considered to be low volume readers compared 
with the stipulated 5000 yearly mammograms which European guidelines recommend.
3,38
 As 
this was the first unit on the island using direct digital mammography, radiologists were new 
to the equipment possibly leading to increased recall rates.
39
 Such high recall rates may also 
arise from the local absence of consensus or arbitration of double reading. Other studies have 
suggested that double reading by consensus or arbitration, although being more labour 
intensive, decreases the recall rate.
7
 
 
The local Further Assessment Rate exceeded European guidelines for the same reasons since 
the recall rate is the summation of further assessment and TR rates.
13
 The small number of 
invasive investigations performed locally is considered as a strength since women with 
benign breast disease undergoing invasive investigations report higher levels of stress and 
anxiety lasting for several months after the additional investigations. 
43, 50. 
 
 
A TR rate of 0.26% indicated high image quality locally, as the objective of a screening 
programme is to minimise the number of women undergoing technical recalls while 
achieving the optimum image quality.
20
 To obtain such an excellent TR Rate careful selection 
and training of staff is necessary.  
 
Low predictive value for malignancy in ER has been expressed in various studies
24,25  
being 
consistent with this study’s findings as the majority of cancers were detected at initial screen, 
with only 2 cancers detected at ER stage. Nevertheless the latter could represent late 
diagnosis and failure of the screening and assessment process since women were falsely 
reassured, and ultimately diagnosed with cancer.
4, 51
 
 
Such a promising Breast Cancer Detection Rate could be due to the benefits of direct digital 
mammography when compared to film screen mammography, namely improving detection of 
calcification related malignancies and non-symptomatic cancers. Although European 
guidelines do not specify an upper limit on the desirable levels, a high breast cancer detection 
rate may suggest a longer sojourn time (the period in which the tumour is asymptomatic but 
detectable by screening) than expected and diagnosis of cancers that would not have been 
detected without screening.
52
 However, over diagnosis has to be evaluated carefully with 
tumour characteristics in mind. 
A PPV of the Screening Test of 7.58% can be interpreted as 13 women recalled per cancer 
detected. Thus 13 women had a false positive mammogram for each cancer detected during 
the local first screening round. Studies have shown that false positive mammograms 
negatively affect women’s well-being; experiencing breast cancer related anxiety, worry and 
distress, when compared with women who receive normal mammogram results.
10,11
  Whilst 
false positive mammograms are undesirable, they are necessary to maximise the number of 
small cancers detected. 
 
 
Literature demonstrated that the age of the screened population has an impact on recall rates 
documenting a decline in rates across age and in subsequent screens.
21, 32   
In contrast this 
research showed lower recall rates in the 51 to 55 years age group. Moreover, results revealed 
that younger women were more likely to have a negative diagnosis after the initial 
mammogram, and older women were more likely to be recalled. In this research the age of 
the screened population was 50 to 60 years, whilst in literature the age of the screened 
population was of a wider age span. However, comparing local results to other studies with 
wider age span was still appropriate. 
This may be due to the fact that the programme commenced with the older client spectrum, 
and invited those aged 56 to 60 in the first years and then moved down the age group and 
invited women aged between 51 and 55 in the following years. Thus the reduction in recall 
rates over the years can be attributed to accumulated experience in screening, allowing 
individual radiologists to attain a greater level of experience and competence.  However there 
was no age discrepancy in the local cancer detection rate and PPV of the screening test, 
signifying that mammograms had similar accuracy in both younger and older women.  
 
Limitations 
Limitations included the lacking or varying definitions of recall found in literature. Definition 
evidently affects the recall rate and thereby its relationship with PPV and breast cancer 
detection rate, making comparison of findings difficult. The performance parameters 
measured in this research were based on definitions stated by the European Guidelines
4
, thus 
permitting comparison of findings to acceptable levels set by these guidelines. 
 
Although European Guidelines were much more comprehensive, measuring additional 
screening performance parameters was impractical due to timing restrictions and available 
resources. 
 
Participant related factors such as breast density and the use of HRT were a further limitation. 
These were not utilised for analysis and could have influenced screening performance 
parameters results. Further studies are required to elucidate this issue. 
 
Conclusions 
Through analysis of the first round of the newly implemented MNBSP, it was concluded that 
the programme performed well since most of the performance parameters complied with 
European guidelines. This successful performance may be the result of joint efforts from all 
personnel, comprehensive QA measures and the use of digital techniques. Such positive 
performance can be used to build and maintain a high state of confidence among local 
radiologists and those responsible for the execution of the screening programme. A 
successful performance in the first screening round encourages new and repeat attendance to 
the Maltese screening programme.  
 
This research has established that the local recall and further assessment rates did not comply 
with the acceptable levels set by the European guidelines, uncovering a problem in local 
clinical performance since according to literature high recall rates can cause psychological 
morbidity 
53
 and indicating inefficient use of screening resources.
35
 In attempt to reduce recall 
and further assessment rates, the ongoing education of personnel particularly screening 
radiologists should be assured. Other recommendations include double reading by consensus 
or arbitration and interpretation of a high volume of mammograms. 
 
This study also investigated any association between age and screening performance 
parameters and demonstrated that younger women were more likely to have a negative 
diagnosis after the initial mammogram whereas older women were more likely to be recalled. 
In addition there was no age discrepancy in the local cancer detection rate and PPV of the 
screening test, signifying that mammograms had similar accuracy in both younger and older 
women. Based on these outcomes, it was established that when a cohort is analysed, age is 
not as significant as the screening round itself.  
 
Screening performance results highlight the importance of continuous surveillance of the 
local screening unit in order to sustain and improve performance and effectiveness. Thus it is 
suggested that regular QA is maintained to offer high quality mammographic screening. 
Future research focusing on the effects of mammography equipment used, training of 
radiologists, volumes of mammograms read, and double-reading by arbitration is 
recommended.  
 
 Conflict of Interest Statement 
Conflicts of Interest: None 
3803 Words 
References 
References 
1. Ministry for Health. Breast Care. Available at: 
https://ehealth.gov.mt/healthportal/health_institutions/hospital_services/mater_dei_ho
spital/surgical_outpatients/breast_care/bstcare_default.aspx 2013 (Accessed: 06 
January 14). 
2. Bezzina P. Exploring the Practice of Radiographers in the Mammography Unit of a 
General Hospital in Malta: A case study. PhD Thesis. University of East Anglia; 
2007.   
3. Michell M. J. Contemporary Issues in Cancer Imaging: Breast Cancer. New York: 
Cambridge University Press; 2010. 
4. Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L. European 
guidelines for quality assurance in breast cancer screening and diagnosis. 4
th
 ed. 
Belgium: European Communities; 2006.  
5. Azavedo E, Zackrisson S, Mejàre I, Heibert Arnlind M. Is single reading with 
computer-aided detection (CAD) as good as double reading in mammography 
screening? A systematic review. BMC Medical Imaging 2012;12:22. 
6. Shaw C, Flanagan F, Fenlon H, McNicholas M. Consensus review of discordant 
findings maximizes cancer detection rate in double-reader screening mammography: 
Irish national breast screening program experience. Radiology 2009;250:354-62. 
7. Hofvind S, Geller B, Rosenberg R, Skaane P. Screening-detected breast cancers: 
Discordant independent double reading in a population-based screening program. 
Radiology 2009;253:652-60. 
8. Patnick J. NHS Breast Screening Programme Annual Review 2012. Sheffield: NHS 
Breast Screening Programme; 2012. 
9. Giordano L, von Karsa L, Tomatis M, Majek O, de Wolf C, Lancucki L, et al. 
Mammographic screening programmes in Europe: organization, coverage and 
participation. J Med Screen 2012;19:72-82.  
10. DeFrank J, Rimer B, Bowling J, Earp J, Breslau E, Brewer T. Influence of false-
positive mammography results on subsequent screening: do physician 
recommendations buffer negative effects? J Med Screen 2012;19:35-41. 
11. Keyzer-Dekker CMG, De Vries J, van Esch L, Ernst MF, Nieuwenhuijzen GAP, 
Roukema JA, et al. Anxiety after an abnormal screening mammogram is a serious 
problem. Breast J 2012;21:83-8.  
12. Tabar L, Tot T, Dean PB. Breast Cancer - The Art and Science of Early Detection 
with Mammography: Perception, Interpretation, Histopathologic Correlation. 1st ed. 
USA: Thieme; 2004. 
13. Liston J, Wilson R. Clinical Guidelines for Breast Cancer Screening Assessment. 
NHSBSP Publication no 49. 3
rd
 ed. Sheffield: NHS Cancer Screening Programmes; 
2010 
14. National Quality Assurance Coordinating Group for Radiography. Quality Assurance 
Guidelines for Mammography including Radiographic Quality Control. NHSBSP 
Publication No. 63. Sheffield: NHS Cancer Screening Programmes; 2006.  
15. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. Estimates of worldwide 
burden of cancer in 2008: GLOBOCAN 2008.  Int J Cancer 2010;127: 2893-917.  
16. Feig S. Adverse effects of screening mammography. Radiol Clin North Am  
2004;42:807-19. 
17. Otten J, Karssemeijer N, Hendricks J, Groenewound J, Fracheboud J, Verbeek A, et 
al. Effect of recall rate on earlier screen detection of breast cancers based on the 
Dutch performance indicators. J Natl Cancer Inst 2005;97:748-54.  
18. Pharoah P, Sewell B, Fitzsimmons D, Bennet H, Pashayan N. Cost effectiveness of 
the NHS breast screening programme: life table model. BMJ  2013;346:15.  
19. Esserman L, Cowley H, Eberle C, Kirkpatrick A, Chang S, et al. Improving the 
accuracy of mammography: volume and outcome relationships. J Natl Cancer Inst 
2002;94:369-75.   
20. Hofvind S, Ponti A, Patnick J, Ascunce N, Njor S, Broeders M, et al. False-positive 
results in mammographic screening for breast cancer in Europe: a literature and 
survey of service screening programmes. J Med Screen 2012;19:57-66.   
21. Yankaskas BC, Klabunde CN, Ancelle-Park R, Renner G, Wang H, Fracheboud J, et 
al. International comparison of performance measures for screening mammography: 
can it be done?. J Med Screen 2004;11:187-193.  
22. Macmillan Cancer Support. Possible results of breast assessment. Available at: 
http://www.macmillan.org.uk/Cancerinformation/Testsscreening/Breastscreening/Ass
essmentresults.aspx 2014 (Accessed: 26 April 2014).  
23. Wilson R, Liston J. Quality Assurance Guidelines for Breast Cancer Screening 
Radiology. NHSBSP Publication No 59. Sheffield: NHS Cancer Screening 
Programmes; 2011. 
24. Yasmeen S, Romano PS, Pettinger M, Chlebowski RT, Robbins JA., Lane DS, et al. 
Frequency and Predictive Value of a Mammographic Recommendation for Short-
Interval Follow-Up. J Natl Cancer Inst 2003;95:429-36.  
25. Pritchard MG, Kearins O, Lawrence G. Audit of short-term recall in the National 
Health Service Breast Screening Programme in the West Midlands. Breast Cancer 
Res 2006;8:48. 
26. NHS Breast Screening Programme. Consolidated guidance on standards for the NHS 
breast screening programme. Sheffield UK: NHSBSP Publications; 2005. 
27. Bennett R. Blanks R. Should a standard be defined for the Positive Predictive Value 
(PPV) of recall in the UK NHS Breast Screening Programme?, Breast, 2007;16:55-9. 
28.  Cancer Research UK. Breast Screening other issues. Available at: 
http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/breast/screening/Other-Issues/ 2012 (Accessed: 10 April 2014).  
29. Lynge E, Olsen AH, Fracheboud J, Patnick J. Reporting of performance indicators of 
mammography screening in Europe. Eur J Cancer Prev 2003;12:213-22.  
30. Biesheuvel C, Weigel S, Heindela W. Mammography Screening: Evidence, History 
and Current Practice in Germany and Other European Countries. Breast Care 
2011;6:104-9.  
31. Yankaskas BC, Cleveland RJ, Schell MJ, Kozar R. Association of recall rates with 
sensitivity and positive predictive values of screening mammography. AJR Am J 
Roentgenol 2001;177:543-9.  
32. Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM, 
et al. Individual and combined effects of age, breast density, and hormone 
replacement therapy use on the accuracy of screening mammography. Ann Intern Med 
2003;138:168-75.  
33. Dean P, Pamilo M. Screening Mammography in Finland - 1.5 Million Examinations 
with 97 percent speciﬁcity. Mammography Working Group, Radiological Society of 
Finland. Acta Oncol 1999;38:47-54.  
34. Broeders M, Scharpantgen A, Ascunce N, Gairard B, Olsen A, et al. Comparison of 
early performance indicators for screening projects within the European Breast 
Cancer Network: 1989-2000. Eur J Cancer Prev 2005;14:107-16. 
35.  Castells X, Molins E, Macia` F. Cumulative false positive recall rate and association 
with participant related factors in a population based breast cancer screening 
programme. J Epidemiol Community Health 2006;60:316-21.  
36. Hofvind S, Thoresen S, Tretli S. The cumulative risk of a false-positive recall in the 
Norwegian breast cancer screening program. Cancer 2004;101:1501-7.  
37. Bond M, Pavey T, Welch K, Cooper C, Garside R, Dean S, et al. Systematic review 
of the psychological consequences of false-positive screening mammograms. Health 
Technol Assess 2013;17:1-70.   
38. Austoker J, Ong G. Written information needs of women who are recalled for further 
investigation of breast screening: Results of a multicentre study. J Med Screen 
1994;1: 238–44. 
39. Scaf-Klomp W, Sanderman R, van de Wiel HB, Otter R, van den Heuvel WJ. 
Distressed or relieved? Psychological side effects of breast cancer screening in The 
Netherlands. J Epidemiol Com Health 1997;51:705–10. 
40. Sandin B, Chorot P, Valiente RM, Lostao L, Santed MA. Adverse psychological 
effects in women attending a second-stage breast cancer screening. J Psychosom Res 
2002;52:303-09. 
41. Ekeberg O, Skjauff H, Kåresen R. Screening for breast cancer is associated with a low 
degree of psychological distress. Breast J 2001;10:20-4.  
42. Lampic C, Thurfjell E, Sjödén PO. The influence of a false-positive mammogram on 
a woman’s subsequent behavior for detecting breast cancer. Eur J  Cancer 
2003;39:1730-7. 
43. Brett J, Austoker J. Women who are recalled for further investigation for breast 
screening: psychological consequences 3 years after recall and factors affecting re-
attendance. J Public Health Med 2001;23:292-300. 
44. Chiarelli AM, Moravan V, Halapy E, Majpruz V, Mai V, Tatla RK. Effects of False-
positive result and re-attendance in the Ontario Breast Screening Program. J Med 
Screen 2003;10:129-33.  
45. Schou Bredal I, Kåresen R, Skaane P, Engelstad KS, Ekeberg Ø. Recall 
mammography and psychological distress. Eur J  Cancer 2013;49:805-11. 
46. Álamo-Junquera D, Murta-Nascimento C, Macià F, Baré M, Galcerán J, Ascunce N, 
et al. Effect of false-positive results on re-attendance at breast cancer screening 
programmes in Spain. Eur J Pub Health 2011;22:404-8.  
47. Sim M, Prema Siva S, Ramli I, Fritschi L, Tresham J, et al. Effect of false-positive 
screening mammograms on rescreening in Western Australia. Med J Aust 
2012;196:693-5. 
48. Bowling A. Research Methods In Health. United Kingdom: Open University Press; 
2009. 
49. Munro B. Statistical methods for health care research. 5th ed. Philadelphia: Lippincott 
Williams and Wilkins; 2005.  
50. Witek-Janusek L, Gabram S, Mathews HL. Psychologic stress, reduced NK cell 
activity, and cytokine dysregulation in women experiencing diagnostic breast biopsy. 
Psychoneuroendocrinology 2007;32:22-35.  
51. Ong G, Austoker J, Michell M. Early rescreen/recall in the UK National Health 
Service breast screening programme: epidemiological data. J Med Screen 1998;5:146-
55.  
52. Hofvind S, Geller B, Vacek PM, Thoresen S, Skaane P. Using the European 
guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur J 
Epidemiol 2007;22:447-55. 
53. Tosteson A, Fryback D, Hammond C, Hanna L, Grove M, et al. Consequences of 
false-positive screening mammograms. JAMA Intern Med 2014;174:954-61.  
 
 
  
Table 1: Screening Performance Parameters Definitions and Acceptable Levels for Programmes in their 
First Screening Round 
 
 
 
Screening 
Performance 
Parameters 
Definition  Acceptable  
EU/UK Level 
Recall Rate The number of women who have to physically 
return to the screening unit for a technical recall or 
for further assessment as a proportion of all women 
who had a screening examination. 
< 7 
Technical Recall Rate The number of women who have a repeat 
mammogram because of a technical inadequacy of 
the screening mammogram as a proportion of all 
women who had a screening examination. 
< 3 
Further Assessment 
Rate 
The number of women undergoing additional 
diagnostic techniques (clinical breast examination, 
additional imaging and invasive investigations) to 
clarify the nature of a perceived abnormality 
detected at the screening examination, as a 
proportion of all women who had a screening 
examination.  
< 7 
Early Recall Rate The number of women who are recalled for further 
assessment at an interval shorter than the normal 
interval (locally 3 years) as a proportion of all 
women who had a screening examination. Early 
recalls are performed when the initial further 
assessment examination leads to an equivocal 
diagnosis.  
< 1 
Breast Cancer 
Detection Rate  
The number of in situ and invasive malignant breast 
lesions detected in a screening round per 1000 
women.  
 
The acceptable European breast cancer detection 
rate for screening programmes in their first round, is 
3 times the underlying, expected, breast cancer 
incidence rate in the absence of screening. The age 
standardised breast cancer incidence rate in 2008 
was 0.72 per 1000 Maltese females.
 
≥2.16 
Positive Predictive 
Value of Screening 
Test 
The number of cancers detected as a proportion of 
the women undergoing further assessment 
(excluding technical recalls).  
> 2.7 
Table 2: Data Record Sheet 1 – Outcome of the Initial Screening Mammogram 
 
Age Group 
Total 
 51 to 55 years 56 to 60 years 
Number of Women Screened 6781 5634 12415 
Outcome of the Screening test 
   
Negative 5623 4492 10115 
Radiologist Recommended 
Technical Recalls 
9 23 32 
Actually Performed Technical 
Recalls 
9 23 32 
Radiologist Recommended 
Further Assessment 
1149 1119 2268 
Actually Performed Further 
Assessment 
1143 1114 2257 
  
 
 
Table 3: Data Record Sheet 2 – Investigations performed during Further Assessment Clinics 
  Age Group 
Total  51 to 55 
years 
56 to 60 
years 
Number of additional imaging  1142 1109 2251 
Types of additional imaging       
Further views 907 874 1781 
Ultrasound 567 614 1181 
       
Clinical examination  8 15 23 
       
Interventional procedures  213 214 427 
Cytology       
Radiologist Recommended Cytology  3 9 12 
Actually Performed Cytology 3 9 12 
Core Biopsy       
Radiologist Recommended Core Biopsy  210 206 416 
Actually Performed Core Biopsy 210 205 415 
 
 
 
 
 Table 4: Data Record Sheet 3 – Outcome of the Overall Screening Process and Timing of Breast Cancer 
Detection 
  Age Group 
Total  51 to 55 
years 
56 to 60 
years 
Outcome of screening process       
Negative Examinations  6678 5554 12232 
Early Recalls following Further Assessment 28 28 56 
Ductal  Carcinoma in situ detected 10 17 27 
Invasive Cancer Detected 87 57 144 
Unknown Outcome 6 6 12 
    
Timing of Breast Cancer Detection       
At Initial Screen  95 74 169 
At Early Recall 2 0 2 
 
 
Table 5: Summary of screening performance parameter rates of the Maltese first screening round 
 
Screening Performance Parameters 
51 to 55 
years 
56 to 60 
years 
Total Rates 
Recall Rate (%) 17.07 20.27 18.53 
Technical Repeat Rate (%) 0.13 0.41 0.26 
Further Assessment Rate (%) 16.94 19.86 18.27 
Early Recall Rate (%) 0.41 0.50 0.45 
Breast Cancer Detection Rate (per 1000 women) 14.30 13.13 13.77 
Positive Predictive Value of Screening Test (%) 8.49 6.64 7.58 
 
 
 
 
 
 
 Table 6: MNBSP Screening Performance Parameters Results compared to Acceptable EU/UK Levels 
 
Screening Performance Parameters 
MNBSP 
Results 
Acceptable Level 
EU/UK Guidelines  
Recall Rate (%) 18.53 < 7 
Technical Repeat Rate (%) 0.26 < 3 
Further Assessment Rate (%) 18.27 < 7 
Early Recall Rate (%) 0.45 < 1 
Breast Cancer Detection Rate (per 1000 
women) 
13.77  ≥2.16 
Positive Predictive Value of Screening Test (%) 7.58 > 2.7 
 
 
  
Highlights 
 The Maltese technical and early recall rates complied with European guidelines. 
 Breast cancer detection rate and positive predictive value conformed to guidelines. 
 The recall and further assessment rates exceeded recommended European guidelines. 
 Effect of age on screening parameters is not as significant as the screening round. 
 
